FDA Requires New Warning for NAION Risk Across All GLP-1 Receptor Agonists

The FDA is requiring updated safety labeling for all glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications following an evaluation identifying a potential increased risk of nonarteritic anterior ischemic optic neuropathy (NAION), a rare condition that can cause sudden, painless vision loss. The agency is directing application holders to add information about NAION to the "Warnings and Precautions" section of product labeling.

Unlocking Clinical Trial Enrollment with AI Screening

It’s not a patient population problem. It’s a signal-extraction problem.

Sunil Gupta, MD, and Joshua Koo, MS, BS

Retina Today

KEY TAKEAWAYS Current clinical trial screening methods rely on physician memory or a manual pre-screener, often leading to missed eligible patients, high screen failure rates, and lagging trial enrollment. An investigational AI model can automatically flag eligible candidates, allowing the physician to initiate the trial conversation and potential formal screening on the same day. Using the AI system allowed the Retina Specialty Institute to bring a protocol live in about 4 weeks. Every practice that runs clinical trials knows a particular kind of frustration. You open a new protocol for geographic atrophy, wet AMD, or diabetic macular edema, confident that patient volume will fill it. And then you watch enrollment crawl. The reflex is to assume the shortfall is a supply problem: not enough patients. However, in a busy retina clinic, the eligible patients are there—the problem isn’t patient scarcity, it’s patient identification. On any given clinic day, dozens of patients have the conditions our open protocols were written to study, and the information needed to identify them as trial candidates is already in the record: acuity measurements, medical and treatment histories, laterality notes, and OCT scans. However, we still need a dependable way to identify that information quickly for each patient.

Refractive Considerations for Supraciliary Surgery

Surgically induced astigmatism tracks the corneal incision rather than the implant.

Reena Garg, MD

Glaucoma Today

Key Takeaways Supraciliary glaucoma surgery augments uveoscleral outflow through an ab interno clear corneal microincision and is frequently combined with phacoemulsification. Potential refractive errors may be a transient change from early hypotony or a sustained shift mediated by axial length changes. Because supraciliary surgery uses no scleral flaps, sutures, or bleb, surgically induced astigmatism tracks the corneal incision rather than the implant. Supraciliary glaucoma surgery augments uveoscleral outflow through an ab interno clear corneal microincision and is frequently combined with phacoemulsification. Potential refractive errors may be caused by two distinct processes: (1) a transient change from early hypotony and (2) a sustained shift mediated by axial length (AL) changes. Because supraciliary surgery uses no scleral flaps, sutures, or bleb, surgically induced astigmatism tracks the corneal incision rather than the implant. The effect is akin to that of microincisional cataract surgery alone if the wound is constructed in a similar fashion.1 CASE PRESENTATION A patient with mild to moderate primary open-angle glaucoma on three topical medications presented with a visually significant cataract and an IOP of approximately 24 mm Hg. The patient underwent uncomplicated phacoemulsification through a temporal clear corneal microincision and placement of a Light Adjustable Lens (LAL; RxSight) in the bag, followed by ab interno supraciliary outflow enhancement with bio-reinforcement using the AlloFlo system (Iantrek). Their visual acuity, IOP, and refraction with spherical equivalent were monitored for 3 months (Tables 1–3). Postoperatively, the IOP decreased to 15 mm Hg.

Featured Podcasts

Ophthalmology off the Grid

Open. Outspoken. It's Ophthalmology off the Grid—an honest look at controversial topics in the field.

View Feed

New Retina Radio

New Retina Radio is a place to hear stories about retina that are told nowhere else.

View Feed

Eyewire News: The Podcast

Get the latest information and breaking news in the ophthalmic field.

View Feed

Eyewire News

11.10.2026

FDA Requires New Warning for NAION Risk Across All GLP-1 Receptor Agonists

11.10.2026

Imvionix Acquires US and Canadian Commercial Rights to Beovu from Novartis

11.10.2026

Zeiss Receives Approval in China for PT Lunana Phakic IOL

11.10.2026

Epion Therapeutics Reports Association Between Keratoconus Severity and Endothelial Cell Density in Phase 3 Study

11.10.2026

City Therapeutics Doses First Participant in Phase 1 Trial of CITY-RBP4 for Stargardt Disease

EyewireTV

11.04.2026

The Latest EyewireTV

Astellas Pharmaceuticals

Ocular Therapeutix

Genentech/Roche

Stocks

Cataract

SmartSight NOVA with CenTrax – Intelligent Centration and Eye Tracking for a New Standard of Precision

How Do Different IOL Categories Tolerate Residual Astigmatism?

Quality of Vision with the TECNIS PureSee™ IOL Elevates Extended Depth-of-Focus IOLs

A New Era of Advanced IOLs

Refocusing the Patient Experience—AI and Team-Based Care in Ophthalmology

Decreasing the Medication Burden With iDose TR

11.10.2026

Zeiss Receives Approval in China for PT Lunana Phakic IOL

11.09.2026

Tenpoint Therapeutics Launches Telehealth Prescribing Program for Yuvezzi

11.06.2026

SpaMedica Report Raises Concerns Over Mandatory Cataract Surgery Waiting Times in England

11.06.2026

CMS Establishes Practice Expense Supply Code for TearCare SmartLids

Refractive

Ophthalmic Executives Provide Company Updates (Part 1 of 2)

High Refractive Tolerance and Patient Satisfaction Make the TECNIS PureSee™ EDOF IOL a Welcome Addition to Refractive Cataract Surgery

Interventional Glaucoma: Building a Long-Term Treatment Roadmap

A New Era of Advanced IOLs

Refocusing the Patient Experience—AI and Team-Based Care in Ophthalmology

Quality of Vision with the TECNIS PureSee™ IOL Elevates Extended Depth-of-Focus IOLs

11.09.2026

Tenpoint Therapeutics Launches Telehealth Prescribing Program for Yuvezzi

11.06.2026

CMS Establishes Practice Expense Supply Code for TearCare SmartLids

11.05.2026

Link Biologics Completes IND-Enabling Preclinical Program for Dry Eye Disease Therapy LB001

11.05.2026

Prism Vision Group Acquires Spectrum Vision Partners, Expanding Ophthalmology Network Across Five States

Stay Updated

Follow Eyewire News

Retina

Unlocking Clinical Trial Enrollment with AI Screening

AAO '26: BRUNELLO and LUGANO

Tackling the Documentation Burden

A Guide to Implementing LLMs in Practice

What Aviation Can Teach Us About AI

Encelto Implant Surgery

11.10.2026

Imvionix Acquires US and Canadian Commercial Rights to Beovu from Novartis

11.10.2026

City Therapeutics Doses First Participant in Phase 1 Trial of CITY-RBP4 for Stargardt Disease

11.09.2026

Viridian Therapeutics Reports Positive Phase 1 Results for VRDN-008, Plans Registrational Trial in 2027

11.09.2026

Ianalumab Reduces Disease Activity in Sjögren’s Disease in Two Phase 3 Trials

Glaucoma

Refractive Considerations for Supraciliary Surgery

Ophthalmic Executives Provide Company Updates (Part 1 of 2)

Cataract and Glaucoma: Strategies for Management

Pearls for iTrack Canaloplasty With Goniotomy and iDose TR Implantation

Seen & Heard

Hands-Free Gonioscopy During iStent infinite and iDose TR Implantation

11.09.2026

Tenpoint Therapeutics Launches Telehealth Prescribing Program for Yuvezzi

11.06.2026

Study Links Colder Temperatures to Higher IOP in Patients with Glaucoma

11.06.2026

CMS Establishes Practice Expense Supply Code for TearCare SmartLids

11.05.2026

Link Biologics Completes IND-Enabling Preclinical Program for Dry Eye Disease Therapy LB001